Key result
Antihypertensive treatments including RAS inhibitors and beta-blockers may offer protective effects in Covid-19.
Why the study?
Hypertension was identified as a common comorbidity in patients hospitalized with Covid-19, raising questions about the effects of antihypertensive treatments during the pandemic.
Do antihypertensive treatments (RAS inhibitors, beta-blockers) have protective effects in patients with Covid-19?
Do antihypertensive treatments (RAS inhibitors, beta-blockers) have protective effects in patients with Covid-19?
This review discusses the potential protective effects of antihypertensive medications, including RAS inhibitors and beta-blockers, in patients with COVID-19.
Hypertension was among the most common comorbidities in hospitalized COVID-19 patients; leaves open its independent contribution to outcomes.
From the beginning of the pandemic hypertension appeared as one of the most common comorbidities in patients hospitalised with a Covid-19 infection. Hypertension, diabetes, overweight, chronic pulm...
No takes yet. Share an insight, caveat, or question.
Kjeldsen et al. (2020) studied this question. Antihypertensive treatments, including renin-angiotensin system inhibitors and beta-blockers, may offer potential protective effects in patients with Covid-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: